Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII.

Kearney, Susan; Raffini, Leslie J; Pham, Tan P; Lee, Xin Ying; von Mackensen, Sylvia; Landorph, Andrea; Takedani, Hideyuki; Oldenburg, Johannes

Kearney, Susan; Raffini, Leslie J; Pham, Tan P; Lee, Xin Ying; von Mackensen, Sylvia; Landorph, Andrea; Takedani, Hideyuki; Oldenburg, Johannes.

Afiliación

Kearney S; Center for Bleeding and Clotting Disorders, Children's Hospital Minnesota, Minneapolis, MN, USA.
Raffini LJ; Division of Hematology, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Pham TP; Mapi (an Icon plc company), Boston, MA, USA.
Lee XY; Global Biopharm Patient Access, Biopharm Operations, Novo Nordisk A/S, Copenhagen, Denmark.
von Mackensen S; Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany, s.mackensen@uke.de.
Landorph A; Medical & Science, Biopharm Operations, Novo Nordisk A/S, Copenhagen, Denmark.
Takedani H; Department of Joint Surgery, Research Hospital of the Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Oldenburg J; Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.

Patient Prefer Adherence ; 13: 497-513, 2019.

Article en En | MEDLINE | ID: mdl-31040652